Prostat Kanserinde Kriyoterapi
Özet
Prostat kanseri tedavisinde radikal prostatektomi (RP) veya radyoterapiye (RT) alternatif olarak uygulanan ablasyon tekniklerinden biri olan kriyoterapi, teknolojik gelişmeler ve görüntüleme yöntemlerinin entegrasyonuyla klinik pratikteki rolünü artırmaktadır. Minimum kan kaybı ve ağrı avantajı sunan bu yöntem, açık RP'ye kıyasla daha iyi tolere edilmekte ve spinal anesteziyle uygulanabilmesi sayesinde ileri yaş veya komorbiditeleri olan lokalize prostat kanserli hastalar için güçlü bir alternatif oluşturmaktadır. Tarihsel süreçte, sıvı nitrojenden gazla çalışan (argon ve helyum) üçüncü nesil sistemlere geçiş ve üretral ısıtıcılar ile transrektal ultrason rehberliğinin kullanımı, inkontinans, erektil disfonksiyon ve rekto-üretral fistül gibi komplikasyon oranlarını kritik düzeyde azaltmıştır. Primer tedavide on yıllık kansere özgü sağ kalım oranı %98,1 gibi başarılı seviyelerde seyretmekle birlikte, uzun vadeli karşılaştırmalı verilerin eksikliği nedeniyle kılavuzlar tarafından henüz rutin birincil tedavi olarak önerilmemektedir. Bununla birlikte, RT sonrası lokal nüks durumlarında kurtarma kriyoterapisi ve RP adayı olmayan hastalar için uzman görüşü düzeyinde veya klinik araştırmalar kapsamında değerli bir seçenek olarak kabul edilmektedir.
Cryotherapy, as an ablation technique alternative to radical prostatectomy (RP) or radiotherapy (RT) in prostate cancer treatment, increasingly expands its clinical role through technological advancements and integration of imaging modalities. Offering advantages of minimal blood loss and pain, this procedure is better tolerated compared to open RP and can be performed under spinal anesthesia, making it a viable alternative for elderly or comorbid patients with localized prostate cancer. Historically, the transition from liquid nitrogen to third-generation gas-powered systems (argon and helium), alongside the implementation of urethral warmers and transrectal ultrasound guidance, has significantly mitigated severe complications such as incontinence, erectile dysfunction, and recto-urethral fistulas. Although primary treatment demonstrates a favorable 10-year cancer-specific survival rate of 98.1%, guidelines do not routinely recommend it as a primary standard due to the lack of long-term comparative data. Nevertheless, it is recognized as a valuable option at the expert opinion level or within clinical trials for salvage therapy in local recurrences following RT and for patients who are unsuitable candidates for RP.
Referanslar
Gonder MJ, Soanes WA, Smith V. Experimental Prostate Cryosurgery. Invest Urol. 1964;1: 610–9.
Han K-R, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int. 2004;93: 14–18.
Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL, Tom WL. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer. 1997;79: 963–74.
Lodeizen O, de Bruin M, Eggener S, Crouzet S, Ghai S, Varkarakis I, Katz A, Dominguez-Escrig JL, Pahernik S, de Reijke T, de la Rosette J. Ablation energies for focal treatment of prostate cancer. World J Urol. 2019;37: 409–18.
Gangi A, Tsoumakidou G, Abdelli O, Buy X, de Mathelin M, Jacqmin D, Lang H. Percutaneous MR-guided cryoablation of prostate cancer: initial experience. Eur Radiol. 2012;22: 1829–35.
Bolla M, van Poppel H, editors. Management of Prostate Cancer: A Multidisciplinary Approach [Internet]. Cham: Springer International Publishing; 2017 [cited 2021 Jun 12]. Available from: http://link.springer.com/10.1007/978-3-319-42769-0
Guo X, Liu S, Wang M, Hou H, Wang X, Zhang Z, Liu M, Wang J. Comparing the Oncological Outcomes of Cryoablation vs. Radical Prostatectomy in Low-Intermediate Risk Localized Prostate Cancer. Front Oncol. 2020;10: 1489.
Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, Lieskovsky G, Ukimura O. Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years. Eur Urol. 2012;62: 55–63.
Guo R-Q, Guo X-X, Li Y-M, Bie Z-X, Li B, Li X-G. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021;26: 461–84.
Shah S, Young HN, Cobran EK. Comparative Effectiveness of Conservative Management Compared to Cryotherapy in Localized Prostate Cancer Patients. Am J Mens Health. 2018;12: 1681–91.
Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2019;22: 309–16.
Bauman G, Ding K, Chin J, Nair S, Iaboni A, Crook J, Klotz L, Dearnaley D, Horwitz E, O’Callaghan C. Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis. Cureus [Internet]. 2020 May 6 [cited 2021 Jun 12]; Available from: https://www.cureus.com/articles/30843-cryosurgery-versus-primary-androgen-deprivation-therapy-for-locally-recurrent-prostate-cancer-after-primary-radiotherapy-a-propensity-matched-survival-analysis
Valle LF, Lehrer EJ, Markovic D, Elashoff D, Levin-Epstein R, Karnes RJ, Reiter RE, Rettig M, Calais J, Nickols NG, Dess RT, Spratt DE, Steinberg ML, Nguyen PL, Davis BJ, Zaorsky NG, Kishan AU. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. 2020;S0302283820308745.
Badalament RA, Bahn DK, Kim H, Kumar A, Bahn JM, Lee F. Patient-reported complications after cryoablation therapy for prostate cancer. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol. 2000;72: 305–12.
Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single Center Experience with Third-Generation Cryosurgery for Management of Organ-Confined Prostate Cancer: Critical Evaluation of Short-Term Outcomes, Complications, and Patient Quality of Life. J Endourol. 2007;21: 1521–32.
Jones JS, Rewcastle JC, Donnelly BJ, Lugnani FM, Pisters LL, Katz AE. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol. Wolters Kluwer Philadelphia, PA; 180: 554–558, 2008.
Chen C-H, Pu Y-S. Proactive rectal warming during total-gland prostate cryoablation. Cryobiology. 2014;68: 431–5.
Zhou JT, Fang DM, Xia S, Li T, Liu RL. The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis. Clin Transl Oncol. 2019;21: 1152–8.
Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. J Urol. 2018;199: 990–7.
Mottet N., Bellmunt J., Briers E., Bolla M., Bourke L., Cornford P., De Santis M., Henry A., Joniau S., Lam T., Mason M.D., Van den Poel H., Van den Kwast T.H., Rouvière O., Wiegel T. EAU Guidelines: Prostate Cancer [Internet]. Uroweb. 2021 [cited 2021 Jun 20]. Available from: https://uroweb.org/guideline/prostate-cancer/#note_1007
National Comprehensive Cancer Network. Prostate Cancer (version 2.2021) [Internet]. NCCN. 2021 [cited 2021 Jun 21]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
